Matches in Wikidata for { <http://www.wikidata.org/entity/Q47999353> ?p ?o ?g. }
- Q47999353 description "2017 nî lūn-bûn" @default.
- Q47999353 description "2017年の論文" @default.
- Q47999353 description "2017年学术文章" @default.
- Q47999353 description "2017年学术文章" @default.
- Q47999353 description "2017年学术文章" @default.
- Q47999353 description "2017年学术文章" @default.
- Q47999353 description "2017年学术文章" @default.
- Q47999353 description "2017年学术文章" @default.
- Q47999353 description "2017年學術文章" @default.
- Q47999353 description "2017年學術文章" @default.
- Q47999353 description "2017年學術文章" @default.
- Q47999353 description "2017年學術文章" @default.
- Q47999353 description "2017年學術文章" @default.
- Q47999353 description "2017년 논문" @default.
- Q47999353 description "article científic" @default.
- Q47999353 description "article scientific" @default.
- Q47999353 description "article scientifique" @default.
- Q47999353 description "articol științific" @default.
- Q47999353 description "articolo scientifico" @default.
- Q47999353 description "artigo científico" @default.
- Q47999353 description "artigo científico" @default.
- Q47999353 description "artigo científico" @default.
- Q47999353 description "artikel ilmiah" @default.
- Q47999353 description "artikull shkencor" @default.
- Q47999353 description "artikulong pang-agham" @default.
- Q47999353 description "artykuł naukowy" @default.
- Q47999353 description "artículo científico publicado en 2017" @default.
- Q47999353 description "artículu científicu" @default.
- Q47999353 description "bilimsel makale" @default.
- Q47999353 description "bài báo khoa học" @default.
- Q47999353 description "naučni članak" @default.
- Q47999353 description "scienca artikolo" @default.
- Q47999353 description "scientific article published on 30 July 2017" @default.
- Q47999353 description "scientific article published on 30 July 2017" @default.
- Q47999353 description "scientific article published on 30 July 2017" @default.
- Q47999353 description "teaduslik artikkel" @default.
- Q47999353 description "tieteellinen artikkeli" @default.
- Q47999353 description "tudományos cikk" @default.
- Q47999353 description "vedecký článok" @default.
- Q47999353 description "vetenskaplig artikel" @default.
- Q47999353 description "videnskabelig artikel" @default.
- Q47999353 description "vitenskapelig artikkel" @default.
- Q47999353 description "vitskapeleg artikkel" @default.
- Q47999353 description "vědecký článek" @default.
- Q47999353 description "wetenschappelijk artikel" @default.
- Q47999353 description "wissenschaftlicher Artikel" @default.
- Q47999353 description "επιστημονικό άρθρο" @default.
- Q47999353 description "мақолаи илмӣ" @default.
- Q47999353 description "наукова стаття, опублікована в липні 2017" @default.
- Q47999353 description "научна статия" @default.
- Q47999353 description "научная статья" @default.
- Q47999353 description "научни чланак" @default.
- Q47999353 description "научни чланак" @default.
- Q47999353 description "מאמר מדעי" @default.
- Q47999353 description "مقالة علمية نشرت في 30 يوليو 2017" @default.
- Q47999353 description "৩০ জুলাই ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q47999353 description "บทความทางวิทยาศาสตร์" @default.
- Q47999353 description "სამეცნიერო სტატია" @default.
- Q47999353 name "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 name "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 type Item @default.
- Q47999353 label "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 label "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 prefLabel "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 prefLabel "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 P1433 Q47999353-3866C32B-1066-46F0-9A01-AD0ED41120C5 @default.
- Q47999353 P1476 Q47999353-C29AED13-4BD3-4A2D-A23A-0983CB1CAC80 @default.
- Q47999353 P2093 Q47999353-2B12BC44-3080-4E0B-A375-1FDD39F83714 @default.
- Q47999353 P2093 Q47999353-2C449EC2-782D-4CDA-AAAA-F3868DA802A3 @default.
- Q47999353 P2093 Q47999353-330082C2-95CC-4705-BA85-4DD94BB0AB90 @default.
- Q47999353 P2093 Q47999353-38C7E895-138D-47F6-8EB2-95B5E144D129 @default.
- Q47999353 P2093 Q47999353-3E3CF0B2-3EA5-4F9D-8ECB-2BDDDEE1D3B4 @default.
- Q47999353 P2093 Q47999353-42FB259C-6B38-4A97-A4C4-C6668E14293D @default.
- Q47999353 P2093 Q47999353-55FBD485-605E-4162-9193-D572D1CF2ADA @default.
- Q47999353 P2093 Q47999353-571C670A-9B59-4FAB-96F3-D94BA2DA05A4 @default.
- Q47999353 P2093 Q47999353-6AE18A57-DBC5-4140-88FA-BD721B432E6A @default.
- Q47999353 P2093 Q47999353-B92DA9EE-8551-4C10-A7CA-796FDFD46536 @default.
- Q47999353 P2093 Q47999353-C01B7945-960A-4F01-8F0A-9FBA108F6438 @default.
- Q47999353 P2093 Q47999353-CA0F5CC6-A00C-4775-9CEC-93824C6B5871 @default.
- Q47999353 P2093 Q47999353-D3E5BF84-A39F-4846-8439-13F6E003D3C8 @default.
- Q47999353 P2093 Q47999353-E1B2925B-0714-43D1-AE2D-EC0111A2CE09 @default.
- Q47999353 P2093 Q47999353-F0D8402F-9F06-4E15-8BF7-6912D1853A56 @default.
- Q47999353 P304 Q47999353-BDCB2461-BE00-401D-B3E0-4755663EB9C3 @default.
- Q47999353 P31 Q47999353-655F709E-7DA5-4F78-8D84-34262A325482 @default.
- Q47999353 P356 Q47999353-0D8F6C7C-6656-45BA-AB83-050E9B2B3CBD @default.
- Q47999353 P478 Q47999353-435EDFB0-B4FB-4971-8220-B72ADA81437C @default.
- Q47999353 P50 Q47999353-58954885-E605-42B9-8BA0-F42E171E0AB3 @default.
- Q47999353 P50 Q47999353-87FF50BD-6A2D-4707-AC2C-BD18DDD118B0 @default.
- Q47999353 P50 Q47999353-984ADD22-5368-44C6-947A-F7F2C2949427 @default.
- Q47999353 P50 Q47999353-E5816134-2BDA-4712-AAB3-1318D091CC86 @default.
- Q47999353 P577 Q47999353-50865D68-37CD-4227-8486-B3B947A0AA15 @default.
- Q47999353 P698 Q47999353-43B8EB17-C4BB-45E6-A327-BC0DF71119EC @default.
- Q47999353 P921 Q47999353-D3B04958-4A86-40BF-AFE0-C3B1A3B05912 @default.
- Q47999353 P356 J.EJCA.2017.06.037 @default.
- Q47999353 P698 28768217 @default.
- Q47999353 P1433 Q332260 @default.
- Q47999353 P1476 "Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)." @default.
- Q47999353 P2093 "Bernd Gerber" @default.
- Q47999353 P2093 "Carsten Denkert" @default.
- Q47999353 P2093 "Christian Jackisch" @default.